A5091710616- Hemoglobinopathies and Related Disorders
- Iron Metabolism and Disorders
- Erythrocyte Function and Pathophysiology
- Blood groups and transfusion
- Neonatal Health and Biochemistry
- Folate and B Vitamins Research
- Autoimmune and Inflammatory Disorders Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Sphingolipid Metabolism and Signaling
- Complement system in diseases
- Reproductive Health and Contraception
- Genital Health and Disease
- HIV/AIDS drug development and treatment
- Syphilis Diagnosis and Treatment
- Bone and Joint Diseases
- Parvovirus B19 Infection Studies
- Immune Cell Function and Interaction
- Prenatal Screening and Diagnostics
- Neutropenia and Cancer Infections
- Heme Oxygenase-1 and Carbon Monoxide
- Drug Transport and Resistance Mechanisms
- Chronic Lymphocytic Leukemia Research
- Adenosine and Purinergic Signaling
- Hematological disorders and diagnostics
- Hemoglobin structure and function
The University of Texas Health Science Center at Houston
2015-2024
University Physicians
2022-2023
Memorial Hermann–Texas Medical Center
2021-2022
University of Houston
2018-2020
Oaklands Hospital
2019
Sphingosine-1-phosphate (S1P) is a bioactive lipid that regulates multicellular functions through interactions with its receptors on cell surfaces. S1P enriched and stored in erythrocytes; however, it not clear whether alterations are involved the prevalent debilitating hemolytic disorder sickle disease (SCD). Here, using metabolomic screening, we found highly elevated blood of mice humans SCD. In murine models SCD, demonstrated erythrocyte sphingosine kinase 1 (SPHK1) underlies sickling...
Abstract Although Lands’ cycle was discovered in 1958, its function and cellular regulation membrane homeostasis under physiological pathological conditions remain largely unknown. Nonbiased high throughput metabolomic profiling revealed that impaired leading to significantly elevated erythrocyte lysophosphatidylcholine (LysoPC) content circulating arachidonic acid (AA) mice with sickle cell disease (SCD), a prevalent hemolytic genetic disorder. Correcting imbalanced by knockdown of...
Elevated sphingosine 1-phosphate (S1P) is detrimental in Sickle Cell Disease (SCD), but the mechanistic basis remains obscure. Here, we report that increased erythrocyte S1P binds to deoxygenated sickle Hb (deoxyHbS), facilitates deoxyHbS anchoring membrane, induces release of membrane-bound glycolytic enzymes and turn switches glucose flux towards glycolysis relative pentose phosphate pathway (PPP). Suppressed PPP causes compromised glutathione homeostasis oxidative stress, while enhanced...
Etavopivat is an investigational, once daily, oral, selective erythrocyte pyruvate kinase (PKR) activator. A multicenter, randomized, placebo-controlled, double-blind, 3-part, phase 1 study was conducted to characterize the safety and clinical activity of etavopivat. Thirty-six patients with sickle cell disease (SCD) were enrolled into 4 cohorts: single-dose, 2 multiple ascending doses, open-label (OL). In OL cohort, 15 (median age 33.0 years [range, 17-55]) received 400 mg etavopivat daily...
Introduction The incidence of multiple myeloma (MM) in the United States has been increasing over past decades with persistent demographic disparities. Social determinants health (SDOH) were found to affect outcomes among certain diseases. However, there was limited data on impact SDOH MM mortality rates. Our study aimed investigate association between and rates from 2016 2020. Methods County-level Centers for Disease Control Prevention/Agency Toxic Substances Registry Vulnerability Index...
Hemophagocytic lymphohistiocytosis (HLH) is a rare and potential life-threatening clinical syndrome that results from uncontrolled activation of the immune system. Secondary HLH, more commonly observed in adult patients, seen context underlying triggering conditions. Epstein-Barr virus (EBV) has been recognized as leading infectious cause associated with poor outcome. As laboratory features HLH could overlap septic shock most diagnosis especially adults, challenging aspect disease delayed...
An atypical clinical presentation makes TTP diagnosis difficult, which prevents prompt management of TTP. This case highlights the importance early recognition in patients with presentations who may not have expected or laboratory findings. The level suspicion should be especially high young and middle-aged strokes acute coronary syndrome do other risk factors for cardiovascular events. is particularly so those a previous episode subtle abnormalities, suggest potential existence thrombotic...
Continued investigation of comorbid conditions that increase the mortality rate COVID-19 is necessary to provide best care for those affected. This continued push find answers even more important populations with comorbidities are historically under-researched. We performed a retrospective analysis 30 patients sickle cell disease (SCD) who tested positive virus. An each patient's history SCD complications, hydroxyurea usage, comorbidities, and several other factors was identify trends will...
Voxelotor is a first-in-class sickle hemoglobin-polymerization inhibitor that was approved in 2019 by the US Food and Drug Administration for treatment of patients with cell disease (SCD) aged ≥12 years; 2021, approval extended to children SCD 4 11 years. Additionally, both Ministry Health Prevention United Arab Emirates European Commission granted marketing authorization voxelotor September 2021 February 2022, respectively, adults pediatric Thus, additional information on patient experience...
Key Points CD73-mediated adenosine production contributes to SCD pathogenesis by promoting erythrocyte 2,3-BPG and sickling. Specific inhibition of CD73 significantly attenuates disease severity mice provides a novel therapeutic strategy treat SCD.
BACKGROUND:Certain health conditions have been proven to an effect on the severity of COVID-19, disease caused by SAR-COV-2. The list identified comorbid includes hematological diseases, with sickle cell (SCD) falling into this category. CASE REPORT:This case series examines history, presentation, and clinical course 5 patients SCD who tested positive for SAR-COV-2 during spring summer 2020. These experienced COVID-19 severities ranging from a mild cough congestion 8-day hospitalizations...
Background Sickle cell disease ( SCD ) affects millions of people and causes chronic hemolytic anemia leading to vasculopathies such as pulmonary hypertension abnormalities in cardiac function that increase complications mortality. It is therefore crucial identify . We aimed assess the prevalence echocardiographic parameters help cardiopulmonary risk. Methods Ninety‐one patients (53% male), median age 30, body surface area BSA 1.79 m 2 , hemoglobin 8.8 g/ dL creatinine 0.7 mg/ identified....
Here we report a case of atypical thrombotic thrombocytopenic purpura that presented as an ischemic cerebrovascular accident. A 56-year-old man with multiple cardiovascular risk factors sudden left-sided weakness, slurred speech, and left facial droop. He showed mild improvement when he was treated thrombolytic therapy according to the hospital stroke protocol. Later in course, developed thrombocytopenia followed by schistocytes revealed peripheral blood smear other lab abnormalities....
Priapism, an unwanted, painful, prolonged erection that is unrelated to sexual stimulation, a common complication of sickle cell disease (SCD). Priapic events in SCD are stuttering, meaning they occur repeatedly with intervening periods detumescence. Without health care intervention, repeated episodes can lead erectile dysfunction. There limited treatment options for SCD-related priapism and no approved targeted therapies. Crizanlizumab monoclonal antibody binds P-selectin used reduce the...
In 2019, crizanlizumab was approved by the Food and Drug Administration (FDA) to reduce rate of vaso-occlusive crisis in patients with sickle cell disease (SCD). We aimed study real-world effectiveness our comprehensive center. This a retrospective cohort analysis SCD who received at least two consecutive doses crizanlizumab. Clinically significant improvement captured using patient global impression change scale (PGI-C). As December 2022, there were 18 eligible for median age 30.5 years....
Patients with sickle cell disease (SCD) experience a range of clinical symptoms, including acute and chronic pain, fatigue, respiratory problems, as well organ complications that can lead to disability accelerated mortality. Voxelotor is first-in-class therapy targets hemoglobin polymerization, the root cause SCD. It approved by US Food Drug Administration for treatment SCD in patients aged 4 years older European Union United Arab Emirates 12 older. Here, we report single-center both...